SCHEMBL4588257

SCHEMBL4588257

CC(C)C(N)C(=O)NC(Cc1c[nH]cn1)C(=O)NC(CCCCN)C(=O)O.[Mn]

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ SLC15A2 Q16348 1/20 0.48
▸ CPB2 Q96IY4 4/20 0.38
▸ ECE1 P42892 1/20 0.37
▸ GHSR Q92847 1/20 0.37
▸ ERAP2 Q6P179 2/20 0.36
▸ ERAP1 Q9NZ08 2/20 0.36
▸ LNPEP Q9UIQ6 2/20 0.36
▸ GNPAT O15228 1/20 0.36
▸ FOLH1 Q04609 1/20 0.36
▸ OPRM1 P35372 1/20 0.35
▸ OPRK1 P41145 1/20 0.35
▸ CPB1 P15086 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2356070 0.99 SLC15A2 (0.48) SLC15A2CPB2ECE1GHSRERAP2
SCHEMBL2356076 0.99 SLC15A2 (0.48) SLC15A2CPB2ECE1GHSRERAP2
SCHEMBL2242452 0.98 SLC15A2 (0.48) SLC15A2CPB2ECE1GHSRERAP2
SCHEMBL4590038 0.92 SLC15A2 (0.49) SLC15A2CPB2ECE1GHSRERAP2
SCHEMBL4589288 0.92 SLC15A2 (0.49) SLC15A2CPB2ECE1GHSRERAP2
SCHEMBL5969770 0.91 SLC15A2 (0.50) SLC15A2CPB2ECE1GHSRERAP2
SCHEMBL1959812 0.91 SLC15A2 (0.50) SLC15A2CPB2ECE1GHSRERAP2
SCHEMBL1959809 0.91 SLC15A2 (0.50) SLC15A2CPB2ECE1GHSRERAP2
SCHEMBL2247594 0.90 SLC15A2 (0.49) SLC15A2CPB2ECE1GHSRERAP2
SCHEMBL2811601 0.90 SLC15A2 (0.49) SLC15A2CPB2ECE1GHSRERAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN PROCYTE CORPORATION (US) 2008-10-16 — — US disclosed
US-7384916-B2 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2008-06-10 — — US disclosed
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2006-11-02 — — US disclosed
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin PROCYTE CORPORATION (US) 2006-01-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin RBP1, RBP4, SOD1 SLC15A2 2656/4885CPB2 2499/4885ECE1 1203/4885
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin RBP1, RBP4, MC1R SLC15A2 1582/4885CPB2 2600/4885ECE1 1432/4885
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN RBP1, RBP4, SOD1 SLC15A2 2656/4885CPB2 2499/4885ECE1 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback